Actavis taps former Ratiopharm chief as new CEO

Justine Varieur Cadet | | Cardiovascular Business | Structural Heart Disease
Generic pharmaceuticals company Actavis Group has appointed former Ratiopharm leader Claudio Albrecht, PhD, as its new CEO.

Albrecht started his career with Sandoz in 1987 where he served as a managing director in the Netherlands, Germany and the U.S., according to Reykjavik, Iceland-based company. In 2000, he joined generics company Ratiopharm as CEO. In 2008, Albrecht established Cometh, a consultancy that advises pharmaceutical companies, including Actavis, on growth strategies.

Sigurdur Oli Olafsson is standing down as Actavis' CEO, following seven years in senior management roles.



Justine Varieur Cadet

Related Content

Edoxaban could limit blood clots, ‘make life easier’ for heart valve surgery patients
Treating younger patients with TAVR increases risk of death
Self-expanding vs. balloon-expandable TAVR valves: How they compare after 5 years
New data put a spotlight on troubling TAVR trends
How robotic-assisted mitral valve repair compares to conventional surgery
Tricuspid TEER shows clinical efficacy for first time in newest TRILUMINATE data

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup